Venus Remedies has an excellent Product line with monopoly in some products. It is improving its marketing gradually.More than as per insider information the stock is on the radar of some institutional investors.Considering the longer perspective one can accumulate the stock at cmp Rs 264 and on dips up to 250 for a return of 25 % to 40 within next 12 months
Venus Remedies capitalises R&D cost. If R&D costs are expensed, then they would show flat to negative profits in past few years.
ReplyDeleteWhile they keep patenting their drugs, they can turnaround only if they successfully manage to outlicense all these drugs which hasn't seen much success over the past 5 years. The results of the Dec'14 quarter shows a 30% drop in sales - no explation from management in this regard and rising fixed costs eating up their bottomline